4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Treatment Resistant Depression by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 185 ongoing clinical trials involving Treatment Resistant Depression
Of the 185 trials,68 trials are in Phase II
Furthermore, 62 trials are in Phase III

Number of ongoing Clinical Trials (for drugs) involving Treatment Resistant Depression by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Treatment Resistant Depression, a Central Nervous System condition. North America boasts of the highest number of ongoing clinical trials involving Treatment Resistant Depression. Asia-Pacific, and Europe are among some of the other prominent regions involved in Treatment Resistant Depression-related drug trials.

Johnson & Johnson: The leading ongoing Treatment Resistant Depression related clinical trials sponsor

Johnson & Johnson, a Pharmaceuticals and Healthcare company headquarter at Germany, is the top sponsor for Treatment Resistant Depression-related ongoing clinical trials.

King's College London, Washington University School of Medicine, University of Oxford, and National Institute of Mental Health are a few other notable sponsors involving Treatment Resistant Depression. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Treatment Resistant Depression

Fluoxetine hydrochloride and olanzapine (Symbyax), and Olanzapine (Olanzapine) are among the key marketed drugs involving Treatment Resistant Depression.

Fluoxetine hydrochloride and olanzapine (Symbyax) is a fixed dose combination, acts as a typical antipsychotic agent. Fluoxetine hydrochloride and olanzapine functions via 5-Hydroxytryptamine Receptor 2A (5 HT2A or Serotonin Receptor 2A or HTR2A) Antagonist; D2 Dopamine Receptor (Dopamine D2 Receptor or DRD2) Antagonist; Sodium Dependent Serotonin Transporter (5HT Transporter or 5HTT or Solute Carrier Family 6 Member 4 or SLC6A4) Inhibitor mechanism of action. It is formulated as hard gelatin capsules for oral route of administration. It is indicated for the treatment of depressive episodes associated with bipolar I disorder in adults and for the treatment resistant depression associated with major depressive disorder in adults who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode. Fluoxetine hydrochloride and olanzapine was first approved in 2003 and is currently sold in the US by Lilly USA LLC, and Mexico by Eli Lilly Mexico SA CV.

Olanzapine is a benzodiazepene derivative acts as typical antipsychotic agent. Olanzapine function via 5-Hydroxytryptamine Receptor 2A (5 HT2A or Serotonin Receptor 2A or HTR2A) Antagonist; D2 Dopamine Receptor (Dopamine D2 Receptor or DRD2) Antagonist mechanism of action. It is formulated as film coated tablets and tablets for the oral route of administration. Olanzapine is indicated for the treatment of schizophrenia, treatment of moderate to severe manic episode and in patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder. Olanzapine was first approved in 2015 and is currently sold in the US by Sunshine Lake Pharma Co Ltd, China by Yichang Hec Changjiang Pharmaceutical Co Ltd, and Germany by HEC Pharm GmbH.